Sandra Chan and Joanna Tsai entitled “Merger Remedies with Chinese Characteristics” which appeared in the August 2013 issue of CPI Antitrust Chronicle. The authors analyze the remedies imposed by the Chinese Ministry of Commerce (MOFCOM) and discuss briefly the draft regulations that MOFCOM recently issued for public comment. Click below to read the article.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...